Milestone Pharmaceuticals said on Friday the U.S. health regulator had declined to approve its nasal spray to treat a type of ...
Milestone Pharmaceuticals hit another bump in the road in its quest to get Cardamyst approved for paroxysmal supraventricular ...
Clearing clinical and regulatory hurdles in the development of a fast-acting nasal spray for a heart condition has been a ...
Milestone Pharmaceuticals Inc.’s heart rhythm-restoring calcium channel blocker for paroxysmal supraventricular tachycardia (PSVT) has yet another obstacle in its way.
Milestone Pharmaceuticals faces a pivotal FDA PDUFA decision for etripamil in PSVT. Read here for a detailed investment ...
“We are deeply disappointed by the CRL but remain committed to the potential of CARDAMYST as a novel treatment option that can help patients with PSVT. Our team is evaluating the feedback ...
Asianet Newsable on MSN2d
Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Retail’s PositiveShares of Milestone Pharmaceuticals Inc. (MIST) traded 60% lower on Friday after the Food and Drug Administration (FDA) did ...
Findings showed a higher proportion of patients in the etripamil group achieved PSVT conversion to sinus rhythm within 30 minutes compared with those who received placebo. Etripamil was also ...
Milestone Pharmaceuticals said on Friday that the U.S. health regulator had declined to approve its nasal spray to treat a ...
CRL focused on CMC; no clinical issues relating to etripamil raised$69.7M in cash, cash equivalents and short-term investments as of December 31, ...
It is a novel calcium channel blocker nasal spray under clinical development for frequent and often highly symptomatic episodes of PSVT and AFib ... and life-altering heart conditions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback